$4.09
4.34% today
Nasdaq, Feb 28, 05:05 pm CET
ISIN
US8883143096
Symbol
TTNP
Sector
Industry

Titan Pharmaceuticals, Inc. Stock price

$3.92
+0.42 12.00% 1M
-2.81 41.75% 6M
+0.66 20.25% YTD
-4.52 53.55% 1Y
-16.48 80.78% 3Y
-122.14 96.89% 5Y
-574,394.08 100.00% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-0.13 3.21%
ISIN
US8883143096
Symbol
TTNP
Sector
Industry

Key metrics

Market capitalization $3.58m
Enterprise Value $180.00k
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.11
Revenue growth (TTM) Revenue growth -100.00%
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-5.82m
Free Cash Flow (TTM) Free Cash Flow $-5.62m
Cash position $3.40m
EPS (TTM) EPS $-6.89
Short interest 1.36%
Show more

Is Titan Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Financial data from Titan Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.01 0.01
93% 93%
-
-0.01 -0.01
107% 107%
-
- Selling and Administrative Expenses 5.32 5.32
5% 5%
-
- Research and Development Expense 0.49 0.49
83% 83%
-
-5.81 -5.81
26% 26%
-
- Depreciation and Amortization 0.01 0.01
93% 93%
-
EBIT (Operating Income) EBIT -5.82 -5.82
27% 27%
-
Net Profit -5.89 -5.89
5% 5%
-

In millions USD.

Don't miss a Thing! We will send you all news about Titan Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Titan Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
3 months ago
NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan”) today reported that it received a notice (the “5250 Notice”) on November 22, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it was not in compliance with Nasdaq's continued listing requirements under the Nasdaq Listing Rule 5250(c)...

Company Profile

Titan Pharmaceuticals, Inc. engages in development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, ProNeura. Its lead product is Probuphine, a buprenorphine implant for the maintenance treatment of opioid addiction. The company was founded by Louis R. Bucalo in February 7, 1992 and is headquartered in South San Francisco, CA.

Head office United States
CEO Weei Chay
Employees 4
Founded 1992
Website www.titanpharm.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today